Atmo Biosciences Ltd

Atmo Biosciences develops the Atmo Gas Capsule, an ingestible gas-sensing capsule that measures gases as it travels through the gastrointestinal (GI) tract and transmits data wirelessly to be uploaded for clinical analysis. The capsule system is positioned for evaluating gastrointestinal motility disorders by measuring whole gut and regional transit times (e.g., stomach, small bowel, and colon) using signals including temperature, hydrogen and carbon dioxide concentration, as well as indicators such as oxygen level, capsule tumble, and antenna reflectance. The company describes the Atmo Gas Capsule System as having U.S. FDA 510(k) clearance and notes it is commercially available in the United States (with other uses restricted to investigational clinical investigations in other markets). The capsule can be used in a motility study workflow where patients swallow the capsule with an associated standardized meal and physicians later upload and interpret the collected data.

Atmo also describes clinical research and trials centered on comparing the Atmo capsule’s transit and related measurements with predicate wireless motility devices such as SmartPill. Its trial descriptions include pivotal and pilot studies in patients with suspected motility disorders and healthy subjects, with clinicians evaluating whole and regional transit times for conditions such as gastroparesis and slow transit constipation. The clinical research page further lists how investigators can use the capsule to identify gut landmarks and perform whole/regional transit time measures and regional-specific gas profiling (e.g., fermentation-related signals in the colon), supporting investigator-initiated studies and conference proceedings.